Dashboard
Manage Tickers

SRPT Sarepta Therapeutics, Inc.

Nasdaq sarepta.com


$ 17.36 $ -0.76 (-4.19 %)    

Monday, 10-Nov-2025 14:44:51 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 622.79 $ 4.00 (0.65 %)
DIA $ 473.57 $ 1.77 (0.38 %)
SPY $ 680.93 $ 3.76 (0.56 %)
TLT $ 89.56 $ 0.07 (0.08 %)
GLD $ 378.17 $ 2.24 (0.6 %)
$ 17.63
$ 18.13
$ 17.35 x 310
$ 17.36 x 220
$ 17.27 - $ 18.13
$ 10.42 - $ 138.81
4,187,428
na
1.85B
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-02-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-equal-weight-on-sarepta-therapeutics-lowers-price-target-to-20
Barclays Maintains Equal-Weight on Sarepta...
11/05/2025 17:51:56

Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

wells-fargo-maintains-overweight-on-sarepta-therapeutics-lowers-price-target-to-45
Wells Fargo Maintains Overweight on Sarept...
11/05/2025 15:27:42

Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target fro...

guggenheim-maintains-buy-on-sarepta-therapeutics-lowers-price-target-to-19
Guggenheim Maintains Buy on Sarepta Therap...
11/05/2025 15:17:49

Guggenheim analyst Debjit Chattopadhyay maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target ...

this-sarepta-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday
This Sarepta Therapeutics Analyst Turns Bu...
11/05/2025 11:44:29

mizuho-upgrades-sarepta-therapeutics-to-outperform-raises-price-target-to-26
Mizuho Upgrades Sarepta Therapeutics to Ou...
11/05/2025 11:03:54

Mizuho analyst Uy Ear upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Outperform and raises the price target fro...

gold-falls-over-1-uber-shares-decline-after-q3-results
Gold Falls Over 1%; Uber Shares Decline Af...
11/04/2025 17:46:44

sarepta-faces-investor-skepticism-as-duchenne-data-falls-short-of-statistical-significance
Sarepta Faces Investor Skepticism As Duche...
11/04/2025 17:33:41

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevi...

baird-maintains-neutral-on-sarepta-therapeutics-lowers-price-target-to-15
Baird Maintains Neutral on Sarepta Therape...
11/04/2025 17:22:38

Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $21...

sarepta-stock-dumps-pharma-bro-martin-shkreli-still-likes-it
Sarepta Stock Dumps: Pharma Bro Martin Shk...
11/04/2025 17:11:10

Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock. 

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 17:06:03

insperity-posts-downbeat-q3-results-joins-iac-archer-daniels-midland-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Insperity Posts Downbeat Q3 Results, Joins...
11/04/2025 14:00:14

Core News & Articles
Market-Moving News for November 4th
11/04/2025 12:24:43

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patie...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 12:05:48

why-upwork-shares-are-trading-higher-by-over-22-here-are-20-stocks-moving-premarket
Why Upwork Shares Are Trading Higher By Ov...
11/04/2025 11:22:41

sarepta-therapeutics-stock-is-tumbling-after-the-close-heres-why
Sarepta Therapeutics Stock Is Tumbling Aft...
11/03/2025 22:00:54

Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update o...

sarepta-therapeutics-says-essence-study-did-not-achieve-statistical-significance-on-its-primary-endpoint-says-the-study-was-impacted-by-the-covid-19-pandemic-and-when-covid-impacted-data-is-excluded-meaningful-treatment-effect-is-seen-on-the-primary-endpoint
Sarepta Therapeutics Says ESSENCE Study Di...
11/03/2025 21:26:27

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
11/03/2025 21:12:06

sarepta-therapeutics-q3-adj-eps-013-beats-081-estimate-sales-399356m-beat-338710m-estimate
Sarepta Therapeutics Q3 Adj. EPS $(0.13) B...
11/03/2025 21:09:02

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of ...

top-stocks-with-earnings-this-week-joby-ionq-amd-and-more
Top Stocks With Earnings This Week: Joby, ...
11/03/2025 14:14:07

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION